The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Subscribe To Our Newsletter & Stay Updated
